Nutra Pharma Corporation settled its fraud case with the Securities and Exchange Commission on March 7th, just days before jury selection was scheduled to begin. The agreement halted the trial proceedings centered on the company's MyNyloxin product.

The SEC's complaint, filed in late 2018, alleged Nutra Pharma, its CEO Erik Deitsch, and associate Peter McManus manipulated stock prices. They did this through a series of false statements related to MyNyloxin, a pain-relief product distributed via a multi-level marketing (MLM) operation.

Nutra Pharma claimed MyNyloxin's active ingredient was cobra venom. This claim proved entirely fabricated. The company issued a press release announcing the completion of a cobra farm expansion, despite no such farm existing. No cobras were present, and no cobra venom production occurred within the company's operations.

Defendants also falsely stated they milked cobras and operated businesses in India and China. These assertions were untrue. The misinformation aimed to inflate the company's stock value and mislead investors and consumers.

MyNyloxin collapsed in January 2015. A subsequent product, Lumaxa, launched as a reboot but quickly failed. The SEC's lawsuit sought to hold the defendants accountable for these alleged deceptions.

The court granted the settlement motion on March 8th. By March 19th, partial consent judgments were entered against Nutra Pharma, Deitsch, and McManus. These judgments prevent them from future violations of the Securities and Exchange Act. The exact amounts for disgorgement of illegal gains and civil penalties remained undetermined at that time.

Significant progress occurred in early April. On April 1st, the SEC filed a status report confirming that settlement talks with Erik Deitsch and Peter McManus had advanced. Both men had agreed in principle to additional terms, which SEC staff prepared to recommend to the Commission.

Nutra Pharma itself continued its negotiations. The SEC stated it expected to receive further information from the company to resolve its remaining issues.

By April 15th, the SEC confirmed it had received signed settlement agreements from both Deitsch and McManus. These agreements were then forwarded to the SEC's Commissioners for final approval before being submitted to the court. The company's final settlement terms remained pending as the SEC awaited necessary information. The court continues to consider the SEC's request for a May deadline to receive the next status report on the remaining settlement negotiations.